Bologna Products Recall Sparks Nationwide Warning to Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Gaiser's European Style Provisions Inc. is recalling over 143,000 pounds of ready-to-eat bologna products due to "misbranding," according to the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) on Friday.
Newsweek reached out to the company via email for comment.
Why It Matters
Numerous recalls have been initiated in 2025 due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens.
Millions of Americans experience food sensitivities or allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts.
What To Know
In the alert, the FSIS warns that the recalled bologna products contain "meat or poultry source materials" not noted on the product's labels. The goods were produced from March 20, 2025, to June 20, 2025.
The alert has photos of the various products' labels and below is a list of the impacted products, according to the FSIS:
Vacuum-packed packages of "FAMILY TREE BOLOGNA VEAL" containing undeclared pork.
Plastic-wrapped packages of "BABUSHKA'S RECIPE CHICKEN BOLOGNA" containing undeclared pork.
Plastic-wrapped packages of "FANCY BOLOGNA" labeled with pork as an ingredient but containing undeclared beef and chicken.
Vacuum-packed packages of "GAISER'S RUSSIAN BRAND DOKTORSKAYA BOLOGNA" containing undeclared beef.
Plastic-wrapped packages of "GAISER'S BOLOGNA VEAL" containing undeclared chicken and pork.
Plastic-wrapped packages of "GAISER'S TURKEY BOLOGNA" containing undeclared chicken and pork.
Plastic-wrapped packages of "CHICKEN BOLOGNA KYPOYKA PABA" containing undeclared pork.
The FSIS warns that these products were distributed to retailers and wholesalers across the country and have an establishment number of "EST. 5385" inside the U.S. Department of Agriculture inspection mark.
"Some products would have been weighed, wrapped, and labeled in retail store locations at the time of purchase," the FSIS says, adding later that the department is concerned people may have the recalled products in their freezers or refrigerators.
Gaiser's Russian Brand Doktorskaya Bologna can be seen related to a recall on June 27. (Photo from the U.S. Department of Agriculture's Food Safety and Inspection Service.)
Gaiser's Russian Brand Doktorskaya Bologna can be seen related to a recall on June 27. (Photo from the U.S. Department of Agriculture's Food Safety and Inspection Service.)
What People Are Saying
The FSIS in the alert, in part: "The problem was discovered when FSIS was notified by the Office of Inspector General (OIG) of a complaint received through the OIG's hotline. FSIS investigated the complaint and determined that the products contained source materials that were not declared on the label.
"Although FSIS does not expect any adverse health effects for Class III recalled products and there have been no confirmed reports of adverse reactions due to consumption of these products, anyone concerned about an illness should contact a healthcare provider."
What Happens Next
Customers who have purchased the recalled products should not consume them; either throw them away or return the goods to the original place of purchase, the FSIS says.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
RFK Jr's new vaccine panel votes against preservative in flu shots in shock move
A critical federal vaccine panel has recommended against seasonal influenza vaccines containing a specific preservative – a change likely to send shock through the global medical and scientific community and possibly impact future vaccine availability. The panel was unilaterally remade by health secretary Robert F Kennedy Jr, a vaccine skeptic who has urged against the use of thimerosal despite a lack of evidence of real-world harm. Across three votes, members voted in favor of restricting thimerosal in seasonal influenza vaccines across all age groups – with five in favor of the restriction, one abstention and one vote against. 'The risk from influenza is so much greater than the nonexistent – as far as we know – risk from thimerosal,' said Dr Cody Meissner, a panel member and professor of pediatrics at Dartmouth's Geisel School of Medicine who was the lone 'no' vote. 'I would hate for a person not to receive the influenza vaccine because the only availability preparation contains thimerosal – I find that very hard to justify.' The panel, formally called the Advisory Committee for Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC), is a critical link in the vaccine distribution pipeline – informing health insurers and clinicians alike about which vaccines to give patients. Kennedy fired all 17 former members of the panel in June, citing conflicts of interest, and appointed eight new members, all of whom are ideological allies of the secretary. None of the new members have published written conflict of interest disclosures or been added to a Trump administration-developed conflict of interest tracker for ACIP members, as of Thursday morning. 'There is a very big difference between what was shared at the meeting versus what is reality,' said Dr Sean O'Leary, chair of the American Academy of Pediatrics Committee on Infectious Diseases. 'The science on thimerosal is settled, and the rhetoric being used to suggest otherwise is misleading and harmful.' Rather than vote on an agenda that had once included seasonal recommendations for Covid-19 and the vaccine against human papilloma virus (HPV), ACIP added the controversial focus of thimerosal in vaccines. The panel affirmed that the influenza vaccine is recommended for Americans older than six months. Related: RFK Jr will be 'personally responsible' for children's deaths by halting vaccine alliance funding, experts say Although multiple studies have found no real-world harm, the preservative has been a talking point of anti-vaccine advocates for decades. Multiple representatives of physicians associations urged the panel to reject the recommendation against thimerosal in the meeting. Thimerosal is used in about 5% of multidose seasonal influenza vials, and is known to be more cost effective than single-dose formulations. It is unclear how the vote will impact flu vaccine availability before the upcoming flu season, particularly for clinics that rely on such formulations. Thimerosal has been used as a preservative in vaccines since before the second world war. In the early 2000s, thimerosal was removed from all routine pediatric and most adult vaccines as a precautionary measure – a decision that was criticized by experts who argued it sent mixed messages about a preservative that had not been found to cause harm. The issue has since been considered settled by mainstream medicine. Thimerosal is an ethylmercury-based preservative. Ethylmercury is different from the kind of mercury found in seafood, called methylmercury. Ethylmercury has a much shorter half-life in the blood and brain, about seven days and 30 days respectively, compared to methylmercury, which has an approximately 44-58 day half-life and accumulates in the brain. The amount of ethylmercury contained in a flu vaccine (25 micrograms) is about half of that contained in a 3-ounce serving of canned tuna fish (40 micrograms). Repeated, large studies conducted across several countries have found no association between thimerosal and neurological effects. A presentation from CDC career scientists that was initially expected to go through some of this substantial data was removed before the panel reconvened on Thursday. In response to a question about the slapped down presentation, ACIP member Dr Robert Malone, a well-known anti-vaccine activist, said: 'That article was not authorized by the office of the secretary and was removed.' The panel instead heard a presentation from Lyn Redwood, a nurse practitioner who founded the World Mercury Project, the predecessor to Kennedy's anti-vaccine advocacy group Children's Health Defense. Prior to the meeting, her presentation was found to include a reference to a study that appeared to be made up. 'This is an old issue that has been addressed in the past and there are many issues we could discuss,' said Meissner. The best public interest journalism relies on first-hand accounts from people in the know. If you have something to share on this subject you can contact us confidentially using the following methods. Secure Messaging in the Guardian app The Guardian app has a tool to send tips about stories. Messages are end to end encrypted and concealed within the routine activity that every Guardian mobile app performs. This prevents an observer from knowing that you are communicating with us at all, let alone what is being said. If you don't already have the Guardian app, download it (iOS/Android) and go to the menu. Select 'Secure Messaging'. SecureDrop, instant messengers, email, telephone and post See our guide at for alternative methods and the pros and cons of each. Responding to criticism of Redwood's presentation, ACIP chair Dr Martin Kulldorff, a former Harvard professor who was fired for refusing the Covid-19 vaccine, said: 'It's inappropriate to dismiss a presentation just because the person does not have a PhD or MD.' The decision from ACIP could have global implications, because vaccines used around the world rely on thimerosal as a preservative in multidose vials, which are less expensive. 'I know ACIP is focused on the US, but recommendations that the ACIP makes are followed among many countries around the world,' said Meissner. 'Removing thimerosal from all vaccines used in other countries, for example, is going to reduce access to these vaccines, it will increase costs, and I think it's important to note that no study has ever indicated any harm from thimerosal.'
Yahoo
21 minutes ago
- Yahoo
US supreme court rules key provision of Obamacare constitutional
The US supreme court has ruled that a key provision of 'Obamacare', formally known as the Affordable Care Act, is constitutional. The case challenged how members of an obscure but vital healthcare committee are appointed. The committee, the US Preventive Services Task Force (USPSTF), is a panel of 16 volunteer health experts who determine which evidence-based preventive health services private insurance companies must cover without cost for patients. The requirement is a provision of the ACA – and one of the few instances when privately insured American patients pay nothing for healthcare. The case, 'in line with other court decisions, strengthens the control of political appointees over the bureaucracy', said Dorit Reiss, a University of California San Francisco law professor and an expert in health law and vaccine policy. Related: US supreme court rules schools must let kids opt out of LGBTQ+ book readings The case, formally called Kennedy v Braidwood Management, Inc, affirms that final decisions come by secretaries, in this case health secretary Robert F Kennedy Jr, a known vaccine skeptic. 'This makes it harder for Congress to isolate expert decisions from political review. So the stakes in appointing the political heads – in this case the secretary – are very, very high,' said Reiss. While the court affirms the constitutionality of the taskforce itself, it also held that members force can be removed at will by the health secretary, and that the secretary may review the taskforce's recommendations before they take effect. Kennedy used those powers only this June, when he unilaterally fired all sitting members of a critical vaccine advisory panel, and remade the panel with ideological allies. The new panel members then delivered Kennedy a victory by recommending against a vaccine preservative called thimerosal, despite a scientific consensus that the ingredient was safe. The court issued the opinion in a 6-3 ruling. The opinion was written by Justice Brett Kavanaugh, and joined by John Roberts, Sonya Sotomayor, Elena Kagan, Amy Coney Barrett and Ketanji Brown Jackson. In 2020 alone, an estimated 150 million Americans benefited from the preventive healthcare provision, according to the O'Neill Institute at the Georgetown University law center in Washington DC. Although the provision requires insurers to cover a wide range of services – from annual check-ups to cancer screenings and immunizations – the case centered on the provision of Prep, or pre-exposure prophylaxis for HIV. A small group of plaintiffs claimed provision of PrEP violated their religious beliefs. They were represented by Jonathan Mitchell, the former solicitor general of Texas who pioneered the state's 'bounty hunter' abortion law. Their arguments were backed by Republican and conservative groups, although the specific ACA provision was defended by both the Trump and Biden administrations. Major public health groups, hospitals, disease advocacy groups and Democratic attorneys general opposed ending the provision. Although the court affirmed the constitutionality of the panel, it also affirms that any health secretary, including Kennedy, could remake the panel with allies. Related: US supreme court limits federal judges' power to block Trump orders The secretary could 'override experts' conclusions and remove things like PrEP', said Reiss. However, she added that the power was not 'absolute'. If the secretary's recommendation contravened the decision of an expert panel and there was a lawsuit, the secretary would still need to make 'a convincing case that there was a reason to deviate from the panel, if there is a lawsuit', said Reiss. That has left the Aids institute, and other groups who advocate for healthcare access for HIV and Aids patients, to say it 'celebrates' the decision while acknowledging uncertainty about the future. 'I think we have to be worried about what that means for future USPSTF decisions given what has happened with' the vaccine panel, said Rachel Klein, the deputy executive director of the Aids Institute. 'Knowing what preventive care is effective to keeping people healthy – and therefore cost-effective to cover – is crucial to helping people be as healthy as possible. That requires listening to medical and scientific experts. We hope that USPSTF will continue to be a body worthy of our trust to make scientifically sound decisions about preventive services going forward.'
Yahoo
28 minutes ago
- Yahoo
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide. Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages. Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio. America Leans on Hikma represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the Company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients. "We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Dr. Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines." Dr. Bill Larkins, President, Hikma Injectables added, "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines by volume with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients." "As a pharmacist and Chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today," said Rep. Buddy Carter. "Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans' access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete," Rep. Carey said. Hikma remains steadfast in its mission to provide affordable and accessible health care solutions. With this continued investment, Hikma reaffirms its commitment to ensuring a reliable supply of essential medications for all Americans. Contacts : Hikma Pharmaceuticals PLC Investors Susan Ringdal EVP, Strategic Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050 Media Steven Weiss US Communications +1 732 788 8279 About Hikma(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch) Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: View original content to download multimedia: SOURCE Hikma Pharmaceuticals USA Inc.
